| Bioactivity | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3]. |
| Invitro | Rafivirumab 显示出对一系列 RABV 分离株的中和作用[2]。Rafivirumab 与 RABV 糖蛋白的抗原位点 I 结合[3]。Rafivirumab 完全中和野生型 ERA439 和 N336D R346K，EC50 范围在 3 到 5 pg/mL 之间[3]。 |
| In Vivo | Rafivirumab (3-12 μg/kg，肌肉注射) 与 CR4098 一起提高了感染蝙蝠狂犬病病毒的叙利亚仓鼠的存活率[2]。 Animal Model: |
| Name | Rafivirumab |
| CAS | 944548-37-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45. [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48. [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403. |